Alfred Chung

2.2k total citations
90 papers, 1.7k citations indexed

About

Alfred Chung is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Alfred Chung has authored 90 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 29 papers in Oncology and 24 papers in Hematology. Recurrent topics in Alfred Chung's work include Multiple Myeloma Research and Treatments (22 papers), Protein Hydrolysis and Bioactive Peptides (13 papers) and Peptidase Inhibition and Analysis (12 papers). Alfred Chung is often cited by papers focused on Multiple Myeloma Research and Treatments (22 papers), Protein Hydrolysis and Bioactive Peptides (13 papers) and Peptidase Inhibition and Analysis (12 papers). Alfred Chung collaborates with scholars based in United States, Germany and Canada. Alfred Chung's co-authors include James W. Ryan, Una Ryan, Frederic E. Dorer, D. R. Schultz, Vivek Maheshwari, Ravindra Kempaiah, K. Sandy Pang, Larry C. Martin, A. Castro and Albert Castro and has published in prestigious journals such as Journal of Clinical Oncology, Blood and ACS Nano.

In The Last Decade

Alfred Chung

86 papers receiving 1.6k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Alfred Chung 787 406 274 212 200 90 1.7k
Krishna C. Agrawal 912 1.2× 739 1.8× 126 0.5× 97 0.5× 88 0.4× 101 2.6k
Béla Nagy 1.1k 1.4× 174 0.4× 552 2.0× 140 0.7× 124 0.6× 120 2.7k
Makoto Takeuchi 893 1.1× 289 0.7× 103 0.4× 112 0.5× 97 0.5× 106 2.7k
John M. Sanders 1.6k 2.0× 501 1.2× 418 1.5× 60 0.3× 135 0.7× 71 4.0k
Thomas J. Brown 651 0.8× 242 0.6× 76 0.3× 122 0.6× 58 0.3× 66 2.6k
Patrizia Cristofori 621 0.8× 1.0k 2.5× 100 0.4× 65 0.3× 107 0.5× 57 2.1k
Frederick S. Philips 1.1k 1.4× 579 1.4× 93 0.3× 114 0.5× 57 0.3× 71 2.6k
Hendrik Neubert 1.3k 1.6× 238 0.6× 82 0.3× 79 0.4× 49 0.2× 78 2.1k
Patrick J. Creaven 1.4k 1.7× 2.1k 5.1× 112 0.4× 140 0.7× 130 0.7× 127 3.9k
Curt Peterson 1.2k 1.5× 1.1k 2.7× 171 0.6× 298 1.4× 42 0.2× 128 3.5k

Countries citing papers authored by Alfred Chung

Since Specialization
Citations

This map shows the geographic impact of Alfred Chung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfred Chung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfred Chung more than expected).

Fields of papers citing papers by Alfred Chung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfred Chung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfred Chung. The network helps show where Alfred Chung may publish in the future.

Co-authorship network of co-authors of Alfred Chung

This figure shows the co-authorship network connecting the top 25 collaborators of Alfred Chung. A scholar is included among the top collaborators of Alfred Chung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfred Chung. Alfred Chung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chung, Alfred, et al.. (2025). AQUILA: Dousing the Embers of Smoldering Multiple Myeloma With Daratumumab Monotherapy. The Hematologist. 22(2).
2.
Voorhees, Peter M., Anita D’Souza, Alfred Chung, et al.. (2024). Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(16_suppl). 7531–7531. 8 indexed citations
3.
Gaballa, Mahmoud, Omar Castañeda Puglianini, Adam D. Cohen, et al.. (2024). BCMA-directed CART therapy in patients with multiple myeloma and CNS involvement.. Journal of Clinical Oncology. 42(16_suppl). 7519–7519. 1 indexed citations
4.
Reyes, Kevin, Yen‐Chun Liu, Chiung‐Yu Huang, et al.. (2024). Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma. Blood Advances. 8(9). 2207–2216. 15 indexed citations
5.
6.
Gaballa, Mahmoud, Adam D. Cohen, Dan T. Vogl, et al.. (2024). BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Advances. 9(5). 1171–1180. 3 indexed citations
7.
8.
Kennedy, Vanessa E., Nina Shah, Shagun Arora, et al.. (2023). Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis. Current Problems in Cancer. 47(3). 100953–100953. 4 indexed citations
9.
Reyes, Kevin, Chiung‐Yu Huang, Mimi Lo, et al.. (2023). Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma. Transplantation and Cellular Therapy. 29(6). 350–355. 26 indexed citations
10.
Lo, Mimi, Rebecca Young, Ila M. Saunders, et al.. (2023). Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma. Journal of Oncology Pharmacy Practice. 29(7). 1715–1724. 1 indexed citations
11.
Weisel, Katja, Anita D’Souza, David D. Hurd, et al.. (2023). P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere. 7(S3). e0036307–e0036307. 1 indexed citations
12.
Martin, Thomas, et al.. (2023). CT-630 Real World Evaluation of Teclistamab: A Focus on Infections in Patients With Relapsed Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S536–S537. 2 indexed citations
13.
Chung, Alfred, Yanli Hou, Robert S. Ohgami, et al.. (2017). A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. Cancer Genetics. 216-217. 10–15. 14 indexed citations
14.
Katritzky, Alan R., et al.. (2007). Microwave‐Assisted Solid‐Phase Peptide Synthesis Utilizing N‐Fmoc‐Protected (α‐aminoacyl)benzotriazoles. Chemical Biology & Drug Design. 70(5). 465–468. 12 indexed citations
15.
Liu, Lichuan, Yunhai Cui, Alfred Chung, et al.. (2006). Vectorial Transport of Enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in Rat and Human Livers. Journal of Pharmacology and Experimental Therapeutics. 318(1). 395–402. 79 indexed citations
16.
Ryan, James W., et al.. (1994). Estimation of rate constants for reactions of pulmonary microvascular angiotensin converting enzyme with an inhibitor and a substrate in vivo.. Journal of Pharmacology and Experimental Therapeutics. 270(1). 260–268. 1 indexed citations
17.
Pitt, Bruce R., et al.. (1986). Uptake of N-[1 (S)-carboxy-(4-OH-3-125I-phenyl)ethyl]-L-Ala-L-Pro, an inhibitor of angiotensin-converting enzyme by rabbit lungs in situ.. Journal of Pharmacology and Experimental Therapeutics. 238(1). 14–18. 2 indexed citations
18.
Southwick, Stephen M., Alfred Chung, Thomas L. Davenport, & James W. Ryan. (1986). A Rapid, Simple Synthesis and Purification of Abscisic Acid Glucose Ester. PLANT PHYSIOLOGY. 81(1). 323–325. 11 indexed citations
19.
Ryan, James W., Alfred Chung, & Una Ryan. (1980). Angiotensin-converting enzyme: I. New strategies for assay. Environmental Health Perspectives. 35. 165–169. 18 indexed citations
20.
Martín, Luis Cuadrado, et al.. (1979). Mammalian inhibitors of angiotensin converting enzyme (kininase II).. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 120B. 599–606. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Krishna C. Agrawal Breakdown of academic impact, for papers by Béla Nagy Breakdown of academic impact, for papers by Makoto Takeuchi Breakdown of academic impact, for papers by John M. Sanders Breakdown of academic impact, for papers by Thomas J. Brown Breakdown of academic impact, for papers by Patrizia Cristofori Breakdown of academic impact, for papers by Frederick S. Philips Breakdown of academic impact, for papers by Hendrik Neubert Breakdown of academic impact, for papers by Patrick J. Creaven Breakdown of academic impact, for papers by Curt Peterson
Rankless by CCL
2026